Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

NCT00776295 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes

Sponsor

H. Lee Moffitt Cancer Center and Research Institute